Introduction
Head and neck squamous cell carcinoma (HNSCC) is a frequently lethal cancer with few effective therapeutic options. Recent genomic findings in head and neck cancer revealed a wide spectrum of unexpected genetic aberrations(1, 2). This genomic heterogeneity of HNSCC tumors underscores an obstacle to the identification of effective molecular targeting agents likely to benefit the majority of HNSCC patients. To date, there is a translational gap between genomics and treatment selection for HNSCC patients. TP53 mutation is the single most common mutational event. Yet the loss of function of this tumor suppressor gene has remained challenging to exploit therapeutically. Mitogenic pathways are crucial for cancer development and progression. In other malignancies, mutations of growth pathway genes have been shown to result in pathway activation, enhanced tumor growth, and increased sensitivity to agents targeting the mutated pathway. However, the potential of genomics-based therapy selection has not been widely investigated in HNSCC.
We and others recently reported genomic mutational profiles of over 100 HNSCC tumors(1, 2).
Here, we analyzed an additional 45 HNSCC tumors by whole exome sequencing using the Illumina platform. In an effort to identify mutationally altered, targetable mitogenic pathways in HNSCC, we combined all currently available mutational data (from whole-exome sequencing) of 151 HNSCC primary tumors and evaluated the mutational events of genes in three major mitogenic pathways that have been previously implicated in HNSCC pathophysiology, namely the MAPK(3), JAK/STAT (4) , and the PI3K pathways (3) . These key mitogenic pathways are targetable in human cancers with a variety of agents currently in various stages of clinical development.
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Nearly one third of HNSCC tumors harbor PI3K pathway mutations
To date, whole-exome sequencing data of 106 HNSCC tumors are available. Here, we reported the whole-exome sequencing data of additional 45 HNSCC tumors collected at the University of Pittsburgh (Supplementary Table 1) . Our results, similar to previous reports, showed a high degree of inter-tumor mutation heterogeneity, further confirming the complexity of HNSCC biology and the associated challenges in defining subsets of patients likely to respond to specific targeted therapies. With the aim of identifying mutationally altered, targetable mitogenic pathways in HNSCC, we assessed the mutational events of genes comprising three major mitogenic and targetable pathways in HNSCC; the JAK/STAT, MAPK and PI3K pathways. Tables 2A-E) . In contrast to other smokingrelated aerodigestive tract cancers where KRAS is frequently mutated(5), the HNSCC-MAPK mutational profile is characterized primarily by HRAS mutations, which accounted for 7 of the 12 pathway mutations identified. PIK3CA is the most commonly mutated gene in the HNSCC-PI3K mutational profile ( Figure 1B ). These results demonstrate that despite the genomic heterogeneity of HNSCC tumors, the PI3K pathway is the most frequently somatically mutated
Research. A detailed analysis of the PI3K pathway mutational events showed that 19 of the 151 tumors (12.6%) harbor a PIK3CA mutation ( Figure 1B ). This mutation rate is similar to that detected in prior reports of HNSCC tumors (7.4% and 10.8% rate (6, 7) ). Further, we found PIK3CG and PTEN mutations in 4.0% (6/151) of HNSCC tumors, while PIK3R1 (also known as p85), PIK3R5
and PIK3AP1 were mutated in 2.7% tumors (4/151). Other components of the PI3K pathway were mutated in <2% cases ( Figure 1B ). Major downstream effectors of the PI3K pathway, including PDK1, AKT1 were not mutated, while AKT2 and mTOR were only mutated in 1.3% (2 mutations) of HNSCC tumors. Although PIK3CA gene amplification data is not available for the previously sequenced tumors, in the newly added cohort, PIK3CA was amplified in 24.4% (11/45) of the cases.
Previous reports noted loss of heterozygosity (LOH) of the tumor suppressor PTEN in HNSCC, by PCR-based microsatellite analysis primarily using D10S215 and/ D10S541 probes in relatively small HNSCC cohorts (e.g. 17 and 39 tumors, respectively) (8, 9) . Although comprehensive analysis of PTEN copy number was not available in the published genomic HNSCC studies(1, 2), PTEN gene copy number change was analyzed using a highly sensitive Affymetrix Genome-Wide Human SNP Array 6.0 platform in our 45 newly sequenced HNSCC tumors. Our results showed that PTEN gene copy loss (≥1 copy loss) was only found in 8.16%
of cases (4/45), indicating that PTEN loss is not likely to be the primary mediator of PI3K pathway alteration in HNSCC (unlike other cancers such as glioblastoma, where PTEN loss can be as high as 20-60%) (10, 11) . However, all 4 tumors with PTEN gene copy loss expressed The association between PI3K pathway mutations and genomic instability is observed in HNSCC derived from all anatomic sites in our cohort (e.g. oral cavity, pharynx and larynx, data not shown). Mutation rates in laryngeal tumors (186.3±27.1, n=32, data not shown) are significantly higher than the rates of mutation in tumors from the other anatomical locations HPV-positive HNSCC tumors (20%; 3/15 cases) may be driven by PI3K-pathway mutation(s) alone, without an associated increase in underlying genomic instability.
Only advanced stage HNSCC tumors harbor multiple PI3K-pathway mutations
In HNSCC cancers containing PI3K pathway mutations, 21.7% (10/46) harbored mutations in more than one PI3K pathway member genes, indicating that genetic alterations at multiple levels in the PI3K pathway are relatively common in HNSCC (Table 1 ). In contrast, HNSCC tumors rarely, if ever, harbored multiple mutations in the MAPK pathway (0 tumors), or the JAK/STAT pathway (only one contained both JAK3 and STAT1 mutations; HN_63080) ( Figure   1C ). Strikingly, all of these HNSCC tumors (100%; 10/10 cases) with concurrent PI3K mutational events were advanced (Stage IV) ( Table 1) . None of these tumors was associated with HPV infection. These findings suggest that concerted PI3K pathway aberrations may contribute to HNSCC progression. This finding appears to be unique to HNSCC. Examination of recently published tumor datasets including breast, colon and lung SCC showed that only 1/25 breast tumors, 1/27 colon carcinoma, and 0/31 lung SCC tumors harbored multiple PI3K pathway mutations were stage IV (data not shown; cBio portal (13)). While all 10 tumors with multiple PI3K pathway mutations were advanced (Stage IV), there is no significant association between advanced disease and individual PI3K pathway mutations (data not shown).
Additionally, mutation rates do not vary significantly between Stage IV and earlier Stage (I-III) disease (data not shown). In the absence of models assessing the specific contribution of each mutation to cell growth or survival, it is not possible to determine the precise effect of individual mutations in tumors that harbor more than one mutation of genes in the PI3K pathway.
Research. 
PIK3CA canonical and novel mutations increase survival and pathway activation in HNSCC tumors
PIK3CA is a critical gene in the PI3K signaling pathway. In HNSCC tumors, the most common sites of PIK3CA mutations included H1047R/L (8 mutations total), E545K/G (4 mutations) and E542K (3 mutations) (Figure 2A ). All of which represent previously reported canonical ("hotspot") mutation sites. This HNSCC-PIK3CA mutation pattern (~90% of mutations found in the helical/kinase domains), is similar to that observed in cervical, breast and lung SCC cancers, but is distinct from other tumors such as endometrial cancer, lung adenocarcinoma, glioblastoma multiforme, and prostate carcinoma (Supplementary Table 5 ). In addition, we detected 4 previously unreported, novel PIK3CA mutations (R115L, G363A, C971R, R975S). To determine the functional consequences of these mutations we stably expressed, by retroviral infection, each of the novel mutations, and a hotspot mutation (H1047R), in a representative HNSCC cell line that is WT for all PI3K pathway components. Overexpression of WT PIK3CA Figure 2) . In contrast, patient tumorgrafts with WT PIK3CA and low baseline p-AKT levels were not sensitive to the growth inhibitory effects of BEZ-235 ( Figure 3F and Supplementary Figure 3 
Discussion:
The increase in targeted agents for cancer treatment results in an unprecedented opportunity for personalized cancer medicine. Selection of therapies based on mutation status of molecular targets has transformed clinical management and survival of several human malignancies. The EGFR monoclonal antibody cetuximab is the only targeted therapy that is FDA-approved to date for HNSCC treatment, yet there are no biomarkers that can be assessed in the primary tumor to predict clinical responses to this agent. The recent elucidation of HNSCC genomics offers an opportunity to identify genetic subgroups of HNSCC tumors to guide treatment decisions.
In this report, we employed a bioinformatic approach to identifying mutationally altered, Using novel patient-derived tumorgraft models with an oncogenic PIK3CA(E542K) mutation we demonstrated that these tumors are exquisitely sensitivity to a PI3K pathway inhibitor (BEZ-235). Similar results were demonstrated in another HNSCC patient-derived tumorgraft model with a PIK3CA (E110K) mutation, previously reported in breast cancer (21) . In contrast, treatment of human-derived heterotopic tumorgrafts with wildtype PIK3CA and low basal expression levels of phospho-AKT, with a PI3K pathway inhibitor, was ineffective. These findings suggest that: 1) PI3K-pathway inhibitors can be effective for treating HNSCC tumors with PI3K mutations; and 2) mutation-guided treatment responses can be evaluated/monitored using patient-derived HNSCC tumorgraft models in vivo. In fact, early-phase clinical trial results showed that patients with solid tumors harboring a PIK3CA hotspot mutation (H1047R) were found to be responsive to PI3K pathway inhibitors (22) . However, the effects of other PIK3CA mutations on mediating drug sensitivity in HNSCC preclinical models or clinical trials has not been previously reported. Findings from our study implicate that PIK3CA(E542K) mutation, as well as other non-hotspot mutations (such as E110K) may also identify an HNSCC subgroup potentially responsive to PI3K-pathway inhibitors. In particular, our results using HNSCC patient-derived tumorgrafts suggest that HNSCC tumors with activating PIK3CA mutations may be more sensitive to a dual PI3K/mTOR inhibitor (such as BEZ-235) compared to tumors with wildtype PIK3CA (Figures 3E and Supplementary Figure 3 PI3K pathway-mutated HNSCC tumors were found to have a higher rate of non-synonymous mutations, including an increased number of defined cancer gene mutations, compared to tumors without PI3K pathway mutations. This observation implies that the PI3K pathwaymutated HNSCC tumors have "oncogenic" advantage even with genomic instability, and/or that PI3K-mutated HNSCC tumors intrinsically harbor a "mutator" phenotype rendering them more prone to mutation. The oncogenic advantage of PI3K pathway-mutated tumors can be partly explained by PIK3CA "driver" mutations' growth-promoting activity (24) (Figure 2C ), while the "mutator" phenotype of these tumors is supported by the our finding that PI3K pathway-mutated tumors are associated with ARID1A and MLL3 mutations, which are important tumor suppressor genes (15, 16, 25) . It is possible that both the "oncogenic/growth" advantage and "mutator" phenotype associated with PI3K pathway-mutated HNSCC tumors are necessary for HNSCC progression; especially since PI3K pathway mutations in these tumors are not associated with TP53 mutation, a previously recognized tumor suppressor alteration that contributes to HNSCC carcinogenesis. Although the relationship of PI3K pathway mutations and TP53 mutation has not been carefully examined in most cancers, a recent study in bladder cancer showed that PIK3CA mutations were significantly more common in TP53 WT tumors (26) . Hence, PI3K pathway mutations may mediate tumor progression in the absence of TP53 genetic alteration.
Our finding that all 10 HNSCC tumors with concurrent mutations of multiple PI3K-pathway genes were advanced stage cancers (Stage IV) suggests the potential involvement of concurrent alterations of multiple nodes of the PI3K pathway in HNSCC progression. This agrees with the recent report that in addition to PIK3CA mutation, other pathway components such as PIK3R1 and PIK3R2, when mutated, can also serve to drive cell growth/survival (27) .
Although the effects of multiple PI3K pathway mutations on cancer cell growth or progression has not been previously investigated, our results support the possibility that genetic alterations 
at multiple nodes in this oncogenic pathway, a common feature of many solid tumors, may identify a subgroup of cancer patients most likely to respond to PI3K pathway inhibitors. These cumulative findings identify the PI3K pathway as the most frequently mutated mitogenic pathway in HNSCC tumors. Prospective identification of patients whose tumors harbor these mutations is likely to identify a subgroup of individuals who may benefit from treatment with PI3K pathway inhibitors.
Materials and Methods
Additional methods are detailed as Supplementary Information.
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